Employing CETSA® in Primary Screening for p53 Binders

CETSA p53 Screening: Uncovering Potential Cancer Therapeutics Targeting p53, a key tumor suppressor protein often labeled “undruggable,” poses a major challenge in oncology research. Yet, overcoming this challenge could unlock transformative cancer treatments. Our latest study leverages CETSA p53 screening—a technique using the Cellular Thermal Shift Assay—to identify small molecules that bind to p53 in live cells. Specifically, we screened for p53 binders in intact SK-BR-3 breast cancer cells, revealing compounds that not only interact with p53 but also stabilize its active form. These findings open new avenues for targeting p53 in cancers where it plays a critical role. Unlike traditional high-throughput screening (HTS) methods, which often rely on artificial systems, CETSA-b...